PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data

PepGen Inc. (NASDAQ:PEPG) is among the best fast money stocks to buy now. H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 from $8.00, implying a surge of nearly 135%. This optimism stems from the company’s 53.7% mean splicing correction at 15 mg/kg report in its FREEDOM single-dose study for DM1 patients, showcasing the highest level disclosed in DM1 patients till now.

The research firm noted that this nearly 54% splicing correction establishes a new standard, pointing to the high chances of repeat dosing delivering significant functional advancements. While expanding the therapeutic window for PepGen Inc. (NASDAQ:PEPG) to a safe and efficacious dose, this could return massively to real health improvements.

Considering the company’s financials, PepGen Inc. (NASDAQ:PEPG) delivered a return of 34.04% in contrast to the market’s average of 13.10%, reflecting an impressive outperformance of nearly 21%.

PepGen Inc. (NASDAQ:PEPG), headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Incepted in 2018, the company offers PGN-EDO51, PGN-EDODM1, and PGN-EDO53.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.